€30m raised for first-in-class in vivo cell reprogramming platform
Drug Discovery World
MARCH 19, 2024
The therapy has achieved preclinical proof of concept (PoC) in patient-derived ex vivo models as well as rodent in vivo models, inducing strong anti-tumour immunity and abscopal effect, even in a monotherapy setting. This financing also follows a strong pre-clinical package providing PoC for AT-108.
Let's personalize your content